EPOCH Therapy for Relapsed/Refractory Lymphoid Malignancies

DOI Web Site PubMed 1 Citations 18 References
  • DOBASHI Nobuaki
    Department of Hematology/Oncology, Jikei University Hospital Department of Internal Medicine (III), Jikei University School of Medicine
  • USUI Noriko
    Department of Hematology/Oncology, Jikei University Hospital Department of Internal Medicine (III), Jikei University School of Medicine
  • KOBAYASHI Tadashi
    Department of Hematology/Oncology, Jikei University Hospital Department of Internal Medicine (III), Jikei University School of Medicine
  • YAMAZAKI Hiroyuki
    Department of Hematology/Oncology, Jikei University Hospital Department of Internal Medicine (III), Jikei University School of Medicine
  • ASAI Osamu
    Department of Hematology/Oncology, Jikei University Hospital Department of Internal Medicine (III), Jikei University School of Medicine
  • YANO Shingo
    Department of Hematology/Oncology, Jikei University Hospital Department of Internal Medicine (III), Jikei University School of Medicine
  • KATO Akinori
    Department of Hematology/Oncology, Jikei University Hospital Department of Internal Medicine (III), Jikei University School of Medicine
  • WATANABE Hiroshi
    Department of Hematology/Oncology, Jikei University Hospital Department of Internal Medicine (III), Jikei University School of Medicine
  • NAGAMINE Mamoru
    Department of Hematology/Oncology, Jikei University Hospital Department of Internal Medicine (III), Jikei University School of Medicine
  • KATORI Mitsuji
    Department of Hematology/Oncology, Jikei University Hospital Department of Internal Medicine (III), Jikei University School of Medicine
  • TAJIMA Naoko
    Department of Internal Medicine (III), Jikei University School of Medicine
  • KURAISHI Yasunobu
    Department of Hematology/Oncology, Jikei University Hospital Department of Internal Medicine (III), Jikei University School of Medicine

Bibliographic Information

Other Title
  • 再発・治療抵抗性リンパ系腫瘍に対するEPOCH療法の試み
  • サイハツ チリョウ テイコウセイ リンパケイ シュヨウ ニ タイスル EPOC

Search this article

Description

Patients with refractory or relapsed non-Hodgkin's lymphoma (NHL), acute T-cell leukemia (ATL), ATL lymphoma and acute lymphocytic leukemia (ALL) received EPOCH therapy. All were previously treated with doxorubicin (DOX), vincristine (VCR) and other drugs. The EPOCH treatment schedule is consisted with DOX (10 mg/M2/day, 5days c.i.v.), VCR (0.4 mg/M2/day, 4days c.i.v.), etoposide (50 mg/M2/day, 4days c.i.v.), cyclophosphamide (750 mg/M2/day, day 6 i.v.) and prednisolone (60 mg/M2/day, 5days p.o.). Twenty-one patients (ALL: 10, NHL: 8, ATLL: 2, ATL: 1) were assessable for response and toxicity. Two patients with ALL and NHL, respectively, achieved a complete remission and 3 patients obtained partial remission (NHL: 2, ATLL: 1). The hematological toxicity (grade>1) included neutoropenia, anemia and thrombocytopenia, which were observed in 83.3%, 76.7% and 76.7% respectively, of total 30 EPOCH courses. The major non-hematological toxicities were nausea/vomiting, constipation and infection, but most of the toxicity were tolerable with sufficient clinical supportive care. These results indicate that continuous infusion of DOX, VCR and ETP might be effective in patients who were treated with, and presumed to be resistant to the same drugs administrated by bolus infusion.

Journal

  • Rinsho Ketsueki

    Rinsho Ketsueki 39 (4), 267-272, 1998

    The Japanese Society of Hematology

Citations (1)*help

See more

References(18)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top